Treatment of Patients With Major Depressive Disorder With MK0869 - Full Text View

Sponsored by:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00034944

Purpose

A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.

Condition	Intervention	Phase
Major Depressive Disorder	Drug: MK0869, aprepitant Drug: Comparator: placebo	Phase III

MedlinePlus related topics: Depression

Drug Information available for: Aprepitant

Study Type:	Interventional
Study Design:	Treatment, Safety/Efficacy Study
Official Title:	A Double-Blind, Multicenter, Placebo Controlled, Acute and Extension Study of 2 Doses of MK0869 in the Treatment of Patients With Major Depressive Disorder

Further study details as provided by Merck:

Primary Outcome Measures:

Secondary Outcome Measures:

CGI-I Scale score at week 8 and at least a 50% reduction in the HAMD-17 total score.

Estimated Enrollment:	450
Study Start Date:	January 2002

Detailed Description:

The duration of treatment is 8 weeks.

Eligibility

Criteria

Major depressive disorder

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00034944

Locations

United States, Connecticut
Call for information
New Britain, Connecticut, United States, 06050
United States, Florida
Call for information
Altamonte Springs, Florida, United States, 32701
Call for information
Miami, Florida, United States, 33161
United States, Louisiana
Call for information
Shreveport, Louisiana, United States, 71103
United States, Virginia
Call for information
Richmond, Virginia, United States, 23294
United States, Wisconsin
Call for information
Middleton, Wisconsin, United States, 53711-3415

Sponsors and Collaborators

Merck

More Information

Publications:

Study ID Numbers:	2006_403, Formally-22
Study First Received:	May 2, 2002
Last Updated:	July 18, 2006
ClinicalTrials.gov Identifier:	NCT00034944
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Depression
Mental Disorders
Mood Disorders
Depressive Disorder, Major

Depressive Disorder
Aprepitant
Behavioral Symptoms

Additional relevant MeSH terms:

Pathologic Processes
Disease
Autonomic Agents
Therapeutic Uses
Physiological Effects of Drugs

Gastrointestinal Agents
Antiemetics
Peripheral Nervous System Agents
Central Nervous System Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009